HER2在非小细胞肺癌临床分期中的预测价值  

Clinical value of serum HER2 in the staging of non-small cell lung cancer

作　　者：殷子珺 徐萌[1] 李平[1] 谭祎[1] 

机构地区：[1]暨南大学附属第一医院,广东广州510000

出　　处：《现代肿瘤医学》2016年第9期1395-1398,共4页Journal of Modern Oncology

摘　　要：目的：人类表皮生长因子受体2（HER2）可能在肺癌的发生发展中,尤其在表皮生长因子受体1（EG-FR）突变状态下,起着重要作用。我们探讨初治晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）血清HER2表达特征及临床意义。方法：本院肺癌研究所2012年9月到2013年6月血清标本共63例。用酶联免疫吸附测定法（ELISA）检测其外周血清中HER2表达水平。结果：HER2中位浓度为25.78ng/ml（10.29~488.28ng/ml）,HER2浓度在不同的肿瘤大小、淋巴结转移及远处转移均有显著性差异（P=0.007、P=0.024、P=0.046）。与淋巴结转移、远处转移呈负相关（P=0.012,P=0.005）。HER2血清浓度定量与年龄、性别、组织学分类、病理学类型、治疗前CEA浓度、吸烟状态、EGFR突变状态均无统计学意义。结论：在外周血清中检测HER2是可行的,与临床特征存在相关性,HER2在肺癌的发展过程中发挥重要作用。Objective： Human epidermal growth factor receptor 2 （HER2） may be in the development of lung cancer, especially in the EGFR mutation, it plays an important role. Treatment of advanced non - small cell lung cancer（NSCLC） we study the serum HER2 expression and clinical significance. Methods： A total of 63 cases of serum samples were tested by enzyme - linked immunosorbent assay （ELISA） to detect the level of expression of serum HER2. Results：The median concentration of HER2 was 25.78ng/ml （10.29 -488.28ng/ml）, HER2 concentration in different tumor size, lymph node metastasis and distant metastasis were significantly different （P = 0. 007, P = 0. 024, P = 0. 046）. With lymph node metastasis,distant metastasis was negatively correlated （ P = 0. 012, P = 0. 005 ）. HER2 serum concentration was not related with age, gender, histological classification, pathology type, pretreatment CEA concentration, smoking status, EGFR mutations. Conclusion：HER2 in serum is feasible, and correlated with the clinical features.

关 键 词：人类表皮生长因子受体2 非小细胞肺癌 表皮生长因子受体1 血清 

分 类 号：R734.2[医药卫生—肿瘤]